Immunogene blandinger

Foreliggende oppfinnelse angår fusjonspartnere som fungerer som immunologiske fusjonspartnere, som ekspresjonsenhancere, og foretrukket fusjonspartnere med begge funksjonene. Spesielt inneholder fusjonspartnerne et såkalt kolinbindende domene, for eksempel fusjoner omfattende LytA fra Streptococcus...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: GERARD CATHERINE MARIE GHISLAINE, PALMANTIER REMI M, SILVA TERESA ELISA VIRGINIA CABEZON, ELLIS JONATHAN HENRY, HAMBLIN PAUL A, BASSOLS CARLOTA VINALS Y DE
Format: Patent
Sprache:nor
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator GERARD CATHERINE MARIE GHISLAINE
PALMANTIER REMI M
SILVA TERESA ELISA VIRGINIA CABEZON
ELLIS JONATHAN HENRY
HAMBLIN PAUL A
BASSOLS CARLOTA VINALS Y DE
description Foreliggende oppfinnelse angår fusjonspartnere som fungerer som immunologiske fusjonspartnere, som ekspresjonsenhancere, og foretrukket fusjonspartnere med begge funksjonene. Spesielt inneholder fusjonspartnerne et såkalt kolinbindende domene, for eksempel fusjoner omfattende LytA fra Streptococcus pneumoniae, eller pneumococcus-fag CP1 -lysozymet (CPL1) hvori det kolinbindende domenet er modifisert til å inkludere en heterolog T-hjelperepitop, og er fusjonert til antigener, spesielt dårlig immunogene antigener slik som selv-antigner, for eksempel tumorspesifikke eller vevsspesifikke antigener. Oppfinnelsen angår også fusjonsproteiner inneholdende dem, deres fremstilling, deres anvendelse i immunogene blandinger og vaksiner og deres anvendelse i medisin. The present invention relates fusion partners which act as immunological fusion partners, as expression enhancers, and preferably to fusion partners having both functions. In particular the fusion partners contain a so-called choline binding domain, for example fusions comprising LytA from Streptococcus pneumoniae, or the pneumococcal phage CP1 lysozyme (CPL1) wherein the choline binding domain is modified to include a heterologous T-helper epitope, and are fused to antigens, particularly poorly immunogenic antigens such as self-antigens, eg tumour specific or tissue specific antigens. The invention also relates to fusion proteins containing them, to their manufacture, to their use in immunogenic compositions and vaccines and to their use in medicines.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NO20045148LL</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NO20045148LL</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NO20045148LL3</originalsourceid><addsrcrecordid>eNrjZBD1zM0tzctPT81LVUjKScxLycxLTy3iYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyUD1JfF-_kYGBiamhiYWPj7GxKgBAIw6IZw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Immunogene blandinger</title><source>esp@cenet</source><creator>GERARD CATHERINE MARIE GHISLAINE ; PALMANTIER REMI M ; SILVA TERESA ELISA VIRGINIA CABEZON ; ELLIS JONATHAN HENRY ; HAMBLIN PAUL A ; BASSOLS CARLOTA VINALS Y DE</creator><creatorcontrib>GERARD CATHERINE MARIE GHISLAINE ; PALMANTIER REMI M ; SILVA TERESA ELISA VIRGINIA CABEZON ; ELLIS JONATHAN HENRY ; HAMBLIN PAUL A ; BASSOLS CARLOTA VINALS Y DE</creatorcontrib><description>Foreliggende oppfinnelse angår fusjonspartnere som fungerer som immunologiske fusjonspartnere, som ekspresjonsenhancere, og foretrukket fusjonspartnere med begge funksjonene. Spesielt inneholder fusjonspartnerne et såkalt kolinbindende domene, for eksempel fusjoner omfattende LytA fra Streptococcus pneumoniae, eller pneumococcus-fag CP1 -lysozymet (CPL1) hvori det kolinbindende domenet er modifisert til å inkludere en heterolog T-hjelperepitop, og er fusjonert til antigener, spesielt dårlig immunogene antigener slik som selv-antigner, for eksempel tumorspesifikke eller vevsspesifikke antigener. Oppfinnelsen angår også fusjonsproteiner inneholdende dem, deres fremstilling, deres anvendelse i immunogene blandinger og vaksiner og deres anvendelse i medisin. The present invention relates fusion partners which act as immunological fusion partners, as expression enhancers, and preferably to fusion partners having both functions. In particular the fusion partners contain a so-called choline binding domain, for example fusions comprising LytA from Streptococcus pneumoniae, or the pneumococcal phage CP1 lysozyme (CPL1) wherein the choline binding domain is modified to include a heterologous T-helper epitope, and are fused to antigens, particularly poorly immunogenic antigens such as self-antigens, eg tumour specific or tissue specific antigens. The invention also relates to fusion proteins containing them, to their manufacture, to their use in immunogenic compositions and vaccines and to their use in medicines.</description><edition>7</edition><language>nor</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2005</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20050301&amp;DB=EPODOC&amp;CC=NO&amp;NR=20045148L$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20050301&amp;DB=EPODOC&amp;CC=NO&amp;NR=20045148L$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GERARD CATHERINE MARIE GHISLAINE</creatorcontrib><creatorcontrib>PALMANTIER REMI M</creatorcontrib><creatorcontrib>SILVA TERESA ELISA VIRGINIA CABEZON</creatorcontrib><creatorcontrib>ELLIS JONATHAN HENRY</creatorcontrib><creatorcontrib>HAMBLIN PAUL A</creatorcontrib><creatorcontrib>BASSOLS CARLOTA VINALS Y DE</creatorcontrib><title>Immunogene blandinger</title><description>Foreliggende oppfinnelse angår fusjonspartnere som fungerer som immunologiske fusjonspartnere, som ekspresjonsenhancere, og foretrukket fusjonspartnere med begge funksjonene. Spesielt inneholder fusjonspartnerne et såkalt kolinbindende domene, for eksempel fusjoner omfattende LytA fra Streptococcus pneumoniae, eller pneumococcus-fag CP1 -lysozymet (CPL1) hvori det kolinbindende domenet er modifisert til å inkludere en heterolog T-hjelperepitop, og er fusjonert til antigener, spesielt dårlig immunogene antigener slik som selv-antigner, for eksempel tumorspesifikke eller vevsspesifikke antigener. Oppfinnelsen angår også fusjonsproteiner inneholdende dem, deres fremstilling, deres anvendelse i immunogene blandinger og vaksiner og deres anvendelse i medisin. The present invention relates fusion partners which act as immunological fusion partners, as expression enhancers, and preferably to fusion partners having both functions. In particular the fusion partners contain a so-called choline binding domain, for example fusions comprising LytA from Streptococcus pneumoniae, or the pneumococcal phage CP1 lysozyme (CPL1) wherein the choline binding domain is modified to include a heterologous T-helper epitope, and are fused to antigens, particularly poorly immunogenic antigens such as self-antigens, eg tumour specific or tissue specific antigens. The invention also relates to fusion proteins containing them, to their manufacture, to their use in immunogenic compositions and vaccines and to their use in medicines.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2005</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBD1zM0tzctPT81LVUjKScxLycxLTy3iYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyUD1JfF-_kYGBiamhiYWPj7GxKgBAIw6IZw</recordid><startdate>20050301</startdate><enddate>20050301</enddate><creator>GERARD CATHERINE MARIE GHISLAINE</creator><creator>PALMANTIER REMI M</creator><creator>SILVA TERESA ELISA VIRGINIA CABEZON</creator><creator>ELLIS JONATHAN HENRY</creator><creator>HAMBLIN PAUL A</creator><creator>BASSOLS CARLOTA VINALS Y DE</creator><scope>EVB</scope></search><sort><creationdate>20050301</creationdate><title>Immunogene blandinger</title><author>GERARD CATHERINE MARIE GHISLAINE ; PALMANTIER REMI M ; SILVA TERESA ELISA VIRGINIA CABEZON ; ELLIS JONATHAN HENRY ; HAMBLIN PAUL A ; BASSOLS CARLOTA VINALS Y DE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NO20045148LL3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>nor</language><creationdate>2005</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>GERARD CATHERINE MARIE GHISLAINE</creatorcontrib><creatorcontrib>PALMANTIER REMI M</creatorcontrib><creatorcontrib>SILVA TERESA ELISA VIRGINIA CABEZON</creatorcontrib><creatorcontrib>ELLIS JONATHAN HENRY</creatorcontrib><creatorcontrib>HAMBLIN PAUL A</creatorcontrib><creatorcontrib>BASSOLS CARLOTA VINALS Y DE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GERARD CATHERINE MARIE GHISLAINE</au><au>PALMANTIER REMI M</au><au>SILVA TERESA ELISA VIRGINIA CABEZON</au><au>ELLIS JONATHAN HENRY</au><au>HAMBLIN PAUL A</au><au>BASSOLS CARLOTA VINALS Y DE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Immunogene blandinger</title><date>2005-03-01</date><risdate>2005</risdate><abstract>Foreliggende oppfinnelse angår fusjonspartnere som fungerer som immunologiske fusjonspartnere, som ekspresjonsenhancere, og foretrukket fusjonspartnere med begge funksjonene. Spesielt inneholder fusjonspartnerne et såkalt kolinbindende domene, for eksempel fusjoner omfattende LytA fra Streptococcus pneumoniae, eller pneumococcus-fag CP1 -lysozymet (CPL1) hvori det kolinbindende domenet er modifisert til å inkludere en heterolog T-hjelperepitop, og er fusjonert til antigener, spesielt dårlig immunogene antigener slik som selv-antigner, for eksempel tumorspesifikke eller vevsspesifikke antigener. Oppfinnelsen angår også fusjonsproteiner inneholdende dem, deres fremstilling, deres anvendelse i immunogene blandinger og vaksiner og deres anvendelse i medisin. The present invention relates fusion partners which act as immunological fusion partners, as expression enhancers, and preferably to fusion partners having both functions. In particular the fusion partners contain a so-called choline binding domain, for example fusions comprising LytA from Streptococcus pneumoniae, or the pneumococcal phage CP1 lysozyme (CPL1) wherein the choline binding domain is modified to include a heterologous T-helper epitope, and are fused to antigens, particularly poorly immunogenic antigens such as self-antigens, eg tumour specific or tissue specific antigens. The invention also relates to fusion proteins containing them, to their manufacture, to their use in immunogenic compositions and vaccines and to their use in medicines.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language nor
recordid cdi_epo_espacenet_NO20045148LL
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
title Immunogene blandinger
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A38%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GERARD%20CATHERINE%20MARIE%20GHISLAINE&rft.date=2005-03-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENO20045148LL%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true